Celldex Therapeutics, Inc. (CLDX)
Largest Insider Buys in Sector
CLDX Stock Price History Chart
CLDX Stock Performance
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune …
Insider Activity of Celldex Therapeutics, Inc.
Over the last 12 months, insiders at Celldex Therapeutics, Inc. have bought $0 and sold $12.09M worth of Celldex Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Celldex Therapeutics, Inc. have bought $76,744 and sold $5.35M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 430 shares for transaction amount of $19,900 was made by Jimenez Freddy A. (SVP & General Counsel) on 2021‑08‑11.
List of Insider Buy and Sell Transactions, Celldex Therapeutics, Inc.
| 2024-06-14 | Sale | SVP AND CFO | 17,172 0.0259% | $35.42 | $608,315 | +2.94% | ||
| 2024-06-14 | Sale | SR. VP & CPDO | 30,000 0.0446% | $34.87 | $1.05M | +2.94% | ||
| 2024-06-07 | Sale | SR. VP & CPDO | 15,000 0.0226% | $35.06 | $525,873 | +0.99% | ||
| 2024-06-07 | Sale | SVP, CHIEF MEDICAL OFFICER | 45,000 0.0682% | $35.26 | $1.59M | +0.99% | ||
| 2024-06-03 | Sale | SVP & GENERAL COUNSEL | 8,006 0.0122% | $33.60 | $269,002 | +5.74% | ||
| 2024-06-03 | Sale | SR. VP & CCO | 46,844 0.0716% | $33.72 | $1.58M | +5.74% | ||
| 2024-06-03 | Sale | SVP OF REGULATORY AFFAIRS | 58,369 0.089% | $33.65 | $1.96M | +5.74% | ||
| 2024-05-30 | Sale | SVP AND CFO | 35,000 0.0538% | $34.05 | $1.19M | +4.94% | ||
| 2024-05-30 | Sale | SR. VP & CPDO | 38,597 0.0586% | $33.64 | $1.3M | +4.94% | ||
| 2024-05-30 | Sale | SVP OF REGULATORY AFFAIRS | 38,719 0.0595% | $34.07 | $1.32M | +4.94% | ||
| 2024-05-30 | Sale | SVP OF CORP AFFAIRS & ADMIN. | 20,853 0.0317% | $33.73 | $703,334 | +4.94% | ||
| 2022-12-07 | Sale | EXECUTIVE VP & CSO | 16,860 0.0356% | $36.93 | $622,611 | -7.99% | ||
| 2022-08-17 | Sale | SVP, CHIEF MEDICAL OFFICER | 19,000 0.0411% | $37.30 | $708,715 | -4.68% | ||
| 2022-08-17 | Sale | SVP OF CORP AFFAIRS & ADMIN. | 1,355 0.0029% | $36.38 | $49,289 | -4.68% | ||
| 2022-08-15 | Sale | PRESIDENT & CEO | 120,000 0.2564% | $37.66 | $4.52M | -6.53% | ||
| 2022-08-15 | Sale | SR. VP & CCO | 15,328 0.0328% | $37.71 | $578,048 | -6.53% | ||
| 2022-08-11 | Sale | SVP AND CFO | 14,261 0.0324% | $36.76 | $524,304 | +1.90% | ||
| 2021-12-23 | Sale | SVP and CFO | 9,500 0.0203% | $42.00 | $399,000 | -25.17% | ||
| 2021-12-08 | Sale | SVP of Regulatory Affairs | 600 0.0013% | $40.00 | $24,000 | -20.89% | ||
| 2021-12-08 | Sale | Sr. VP &CPDO | 4,000 0.0086% | $40.00 | $160,000 | -20.89% |
Insider Historical Profitability
| Martin Samuel Bates | SVP AND CFO | 28125 0.0424% | $27.86 | 1 | 6 | +500.67% |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | 25924 0.0391% | $27.86 | 1 | 1 | <0.0001% |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 13383 0.0202% | $27.86 | 1 | 4 | +500.67% |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 2115 0.0032% | $27.86 | 1 | 3 | +105.94% |
| Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 1860 0.0028% | $27.86 | 1 | 4 | +275.1% |
Institutional Investor Ownership
| Fidelity Investments | $408.2M | 14.76 | 9.73M | +37.95% | +$112.3M | 0.03 | |
| Wellington Management Company | $320.96M | 11.6 | 7.65M | +18.08% | +$49.14M | 0.05 | |
| BlackRock | $189.37M | 6.85 | 4.51M | +22.75% | +$35.1M | <0.01 | |
| The Vanguard Group | $153.21M | 5.54 | 3.65M | +19.84% | +$25.36M | <0.01 | |
| Eventide Asset Management | $130.91M | 4.73 | 3.12M | -14.07% | -$21.44M | 2.12 |